Gilead Sciences, Inc. GILD
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Gilead Sciences, Inc. gets an algorithmic score of 52/100. It trades at 151.28 $, with a bullish technical trend (RSI 60.1) and 26.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (5.0%).
- Low beta (0.13): defensive profile.
Weaknesses
- Low ROE (-20.7%).
- Thin net margin (-10.6%): vulnerable to costs.
- High leverage (debt/equity 223%): rate-sensitive.
Fundamentals
| Forward P/E | 15.30 |
| PEG | 2.27 |
| P/B | 15.87 |
| EV/EBITDA | 14.30 |
| P/S | 6.16 |
| ROE % | -20.68 |
| ROA % | 14.09 |
| Gross margin % | 79.60 |
| Operating margin % | 33.68 |
| Net margin % | -10.64 |
| Revenue growth % (y/y) | 10.20 |
| Revenue CAGR % | 2.57 |
| Earnings CAGR % | 22.83 |
| Debt/Equity % | 223.47 |
| Current ratio | 1.26 |
| FCF yield % | 5.04 |
| Dividend yield % | 2.17 |
| Payout % | 43.40 |
Returns
| 1 month | +4.4 % |
| 3 months | +20.4 % |
| 6 months | +12.3 % |
| YTD | +26.6 % |
| 1 year | +38.3 % |
| 3 years | +121.7 % |
| 5 years | +152.0 % |
Risk
| 1-year volatility | 26.4 % |
| Beta | 0.13 |
| 5-year max drawdown | -26.6 % |
| Sharpe 1A | 1.21 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.